116 related articles for article (PubMed ID: 6959958)
1. Immunological studies in patients receiving Corynebacterium parvum (C.P.) as immunotherapy for acute myelogenous leukemia (AML).
Pai VR; Shetty PA; Jussawalla DJ
Indian J Cancer; 1982; 19(3):149-52. PubMed ID: 6959958
[No Abstract] [Full Text] [Related]
2. The role of immunotherapy in acute myelogenous leukemia.
Foon KA; Smalley RV; Riggs CW; Gale RP
Arch Intern Med; 1983 Sep; 143(9):1726-31. PubMed ID: 6577818
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy and corynebacterium parvum for induction and maintenance of remission in acute myelogenous leukaemia--a controlled study.
Shetty PA; Pai VR; Jani PH; Antia PK; Shahane AD
Indian J Cancer; 1983; 20(2):119-23. PubMed ID: 6580265
[No Abstract] [Full Text] [Related]
4. Clinical immunotherapy experiences in the Southeastern Cancer Study Group.
Gordon DS
Dev Biol Stand; 1977 Apr 13-15; 38():567-72. PubMed ID: 344110
[TBL] [Abstract][Full Text] [Related]
5. Immunomodulation of NK and ADCC by Corynebacterium parvum in acute myeloid leukaemia patients.
Hokland P; Ellegaard J
Leuk Res; 1985; 9(1):175-84. PubMed ID: 3857405
[TBL] [Abstract][Full Text] [Related]
6. [Management of acute leukemias and linphosarcomas with active immunotherapy (author's transl)].
Mathe G; Amiel JL; Schwarsenberg L; Hyat M; Pouillart P; Schenider M; Cattan A; Jasmin C; Belpomme D; Schulmberger JR; De Vassal F; Musset M; Misset JL
Folia Clin Int (Barc); 1975 Mar; 25(3):131-51. PubMed ID: 1056311
[No Abstract] [Full Text] [Related]
7. Adjuvant immune stimulation with Corynebacterium parvum during maintenance chemotherapy of acute myeloid leukemia. A prospective randomized study.
la Cour Petersen E; Hokland P; Ellegaard J
Cancer Immunol Immunother; 1983; 16(2):88-92. PubMed ID: 6420046
[TBL] [Abstract][Full Text] [Related]
8. Intraperitoneal immunotherapy of human ovarian carcinoma with Corynebacterium parvum.
Bast RC; Berek JS; Obrist R; Griffiths CT; Berkowitz RS; Hacker NF; Parker L; Lagasse LD; Knapp RC
Cancer Res; 1983 Mar; 43(3):1395-401. PubMed ID: 6825108
[TBL] [Abstract][Full Text] [Related]
9. [Immunotherapy of cancer: evolution of concepts and clinical advances].
Baldwin RW
Rev Prat; 1980 Jan; 30(5):221-4, 227-8. PubMed ID: 6929557
[No Abstract] [Full Text] [Related]
10. Immunological response in patients receiving Corynebacterium parvum therapy.
Osborn DE; Castro JE
Clin Oncol; 1977 Jun; 3(2):155-64. PubMed ID: 872468
[No Abstract] [Full Text] [Related]
11. Proceedings: Immunotherapy of Moloney sarcoma virus tumours in mice with Corynebacterium parvum.
Hamilton DN; Bell PR
Br J Surg; 1974 Apr; 61(4):321. PubMed ID: 4832648
[No Abstract] [Full Text] [Related]
12. Local Corynebacterium parvum therapy in early breast cancer: a pilot study.
Boak JL
Clin Oncol; 1978 Sep; 4(3):235-42. PubMed ID: 750126
[No Abstract] [Full Text] [Related]
13. Clinical studies with Corynebacterium parvum.
Mitcheson HD; Castro JE
Dev Biol Stand; 1977 Apr 13-15; 38():509-14. PubMed ID: 344105
[TBL] [Abstract][Full Text] [Related]
14. Immunomodulation by Corynebacterium parvum in normal humans.
Hokland P; Ellegaard J; Heron I
J Immunol; 1980 May; 124(5):2180-5. PubMed ID: 6154095
[TBL] [Abstract][Full Text] [Related]
15. Developmental approaches in immunological control of acute myelogenous leukaemia.
Torelli GF; Orsini E; Guarini A; Kell J; Foà R
Best Pract Res Clin Haematol; 2001 Mar; 14(1):189-209. PubMed ID: 11355931
[TBL] [Abstract][Full Text] [Related]
16. Corynebacterium parvum.
Delmonte L; Oettgen HF; Hirshaut Y; Pinsky CM; Wanebo HJ
Clin Bull; 1976; 6(1):31-4. PubMed ID: 1269143
[No Abstract] [Full Text] [Related]
17. [Hematological observations in patients following immunostimulation through intrapleural application of Corynebacterium parvum].
Karrer K; Denck H; Pridun N
Acta Med Austriaca; 1979; 6(5):209-12. PubMed ID: 233458
[TBL] [Abstract][Full Text] [Related]
18. Large-scale generation of autologous dendritic cells for immunotherapy in patients with acute myeloid leukemia.
Schmitt A; Reinhardt P; Hus I; Tabarkiewicz J; Roliñski J; Barth T; Giannopoulos K; Dmoszyñska A; Wiesneth M; Schmitt M
Transfusion; 2007 Sep; 47(9):1588-94. PubMed ID: 17725721
[TBL] [Abstract][Full Text] [Related]
19. Increasing mixed chimerism defines a high-risk group of childhood acute myelogenous leukemia patients after allogeneic stem cell transplantation where pre-emptive immunotherapy may be effective.
Bader P; Kreyenberg H; Hoelle W; Dueckers G; Kremens B; Dilloo D; Sykora KW; Niemeyer C; Reinhardt D; Vormoor J; Gruhn B; Lang P; Greil J; Handgretinger R; Niethammer D; Klingebiel T; Beck JF
Bone Marrow Transplant; 2004 Apr; 33(8):815-21. PubMed ID: 14990984
[TBL] [Abstract][Full Text] [Related]
20. Immunocompetence, immunodeficiency and prognosis in cancer.
Hersh EM; Gutterman JU; Mavligit GM; Mountain CW; McBride CM; Brugess MA; Lurie PM; Zelen M; Takita H; Vincent RG
Ann N Y Acad Sci; 1976; 276():386-406. PubMed ID: 800324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
